Medcan Introduces Galleri® Multi-Cancer Early Detection Test to Canada

Groundbreaking blood test can screen for over 50 types of cancer before symptoms appear

TORONTO — Medcan, a leader in proactive health and wellness, has announced the Canadian launch of the Galleri® Multi-Cancer Early Detection (MCED) Test by GRAIL, a pioneering blood-based screening that can identify signals from more than 50 types of cancer before symptoms develop.

Now available exclusively at Medcan clinics, Galleri represents a major advancement in preventive medicine — offering Canadians access to a test that detects cancers that currently lack routine screening options, including pancreatic, ovarian, esophageal, and liver cancers.

“The Galleri test empowers us to detect cancer earlier, often before symptoms appear,” said Dr. Peter Nord, Chief Medical Officer at Medcan. “That early insight allows for earlier diagnosis and treatment, which the literature confirms can result in improved health outcomes for our clients.”

“As a leader in proactive health, Medcan is proud to bring this innovation to Canadians,” added Shaun Francis, Chair and CEO of Medcan. “The Galleri test expands what’s possible in early cancer detection and reinforces our mission to help people live well, for life.”

How the Galleri Test Works

Through a simple blood draw taken at Medcan’s Toronto or Oakville clinics, the Galleri test screens for unique DNA “fingerprints” shed by cancer cells into the bloodstream.

• Clients can complete the test alone or alongside their Annual Health Assessment.

• Results are available in approximately four weeks, accompanied by personalized guidance from Medcan’s clinical team.

• If a cancer signal is detected, the test can identify where in the body it likely originated, allowing doctors to guide next-step diagnostics.

• If no cancer signal is detected, clients are advised to continue with their regular screening schedule.

Clinical Evidence and Canadian Involvement

The launch follows compelling new findings from PATHFINDER 2, a large-scale, multi-center, interventional study involving approximately 35,000 adults over age 50. Conducted in part at University Health Network (UHN) — Canada’s largest academic hospital network — the study demonstrated the test’s safety, performance, and ability to guide early detection.

With a clinical program encompassing more than 385,000 participants globally, the Galleri test is one of the most rigorously studied innovations in oncology. It is currently the only multi-cancer detection test supported by results from an interventional screening study in individuals without symptoms.

A New Era of Preventive Medicine

Medcan’s introduction of the Galleri test aligns with its focus on proactive health — empowering Canadians to take preventive action before illness develops.

Eligible adults, particularly those aged 50 and older, can learn more about eligibility and booking by visiting medcan.com/Galleri.

About Medcan

Founded in Toronto, Medcan is a global leader in proactive health and wellness, offering evidence-based primary and specialty care designed to improve long-term wellbeing. With clinics in Toronto, Oakville, Collingwood, and Muskoka, Medcan delivers comprehensive health assessments and personalized care to individuals, families, and organizations. Learn more at medcan.com.

Follow GTA Today on social media for more local news and updates. #GTAToday